IP Library Granted Patent US 7,122,018
Granted Patent B2
US 7,122,018 · App. 11/021,109 · Granted Oct 17, 2006

Device and method for treatment of wounds with nitric oxide

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,122,018
App. No.
11/021,109
Granted
Oct 17, 2006
Kind
B2
Abstract

Topical exposure of nitric oxide gas to wounds such as chronic non-healing wounds may be beneficial in promoting healing and preparing the wound bed for further treatment and recovery. Nitric oxide gas may be used to reduce the microbial infection, manage exudates secretion by reducing inflammation, upregulate expression of endogenous collagenase to locally debride the wound, and regulate the formation of collagen. High concentration of nitric oxide ranging from 160–400 ppm may be used without inducing toxicity in the healthy cells around a wound site. Exposure to the high concentration for a first treatment period reduces the microbial burden and inflammation, and increases collagenase expression to debride necrotic tissue at the wound site. After a first treatment period, a second treatment period at a lower concentration of nitric oxide, preferably ranging from 5–20 ppm may be used to restore the balance of nitric oxide and induce collagen expression aiding in the wound closure.

Claims (22)

1. A method to promote healing of a wound of a subject, the method comprising the steps of:

providing a flow-controlled source of nitric oxide gas;

exposing the wound to a high concentration of exogenous nitric oxide gas for a treatment period without inducing toxicity to the subject or the healthy cells surrounding the wound; and

exposing the wound to a decreased concentration of exogenous nitric oxide gas for a second treatment period sufficient to increase the expression of collagen MRNA.

2. The method of claim 1 , further comprising the step of monitoring the concentrations of nitric oxide gas.

3. The method of claim 2 , wherein the decreased concentration of nitric oxide gas is about 5 ppm.

4. The method of claim 2 , wherein the treatment period is about 7 hours and the second treatment period is at least about 7 hours.

5. The method of claim 1 , further comprising the step of monitoring of the levels of collagenase produced by cells surrounding the wound.

6. The method of claim 1 , further comprising the step of monitoring the levels of collagen produced by cells surrounding the wound.

7. The method of claim 1 , further comprising the step of removing of excess exudate from the wound.

8. The method of claim 1 , wherein the high concentration of nitric oxide gas is greater than about 200 ppm.

9. The method of claim 8 , wherein the high concentration of nitric oxide gas is about 200 ppm to 400 ppm.

10. The method of claim 1 , wherein the treatment period is at least about 7 hours.

11. The method of claim 10 , wherein the exposure to the high concentration of nitric oxide gas in the first treatment period is continuous.

12. A method of reducing scarring in a healing process of a wound, the method comprising the steps of:

providing a flow-controlled source of nitric oxide gas;

exposing the wound to a high concentration of exogenous nitric oxide gas for a treatment period without inducing toxicity to the subject or to healthy cells surrounding the wound,

exposing the wound to a decreased concentration of exogenous nitric oxide gas for a second treatment period sufficient to increase the expression of collagen mRNA; and

exposing the wound to a third concentration of exogenous nitric oxide gas for a third treatment period, wherein the third concentration is between the high concentration and the decreased concentration.

13. The method of claim 12 , wherein the high concentration ranges from about 200 ppm to 400 ppm, the decreased concentration ranges from about 5 ppm to 20 ppm, and the third concentration ranges from about 20 ppm to 200 ppm.

14. The method of claim 12 wherein the first treatment period is at least seven hours in a day, the second treatment period ranges from 5–12 hours a day, and the third treatment period ranges from about 5–12 hours a day.

15. The method of claim 14 wherein the first treatment period, the second treatment period, and the third treatment period are repeated for multiple days.

Assignments (12)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 12, 2025
From: SENSORMEDICS CORPORATION
To: ZOLL MEDICAL CORPORATION
Reel/Frame 072869/0633 →
SECURITY INTEREST Recorded May 9, 2019
From: SENSORMEDICS CORPORATION
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 049126/0905 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 21, 2018
From: AIT THERAPEUTICS, INC.
To: ADVANCED INHALATION THERAPIES (AIT) LTD.
Reel/Frame 047562/0295 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2018
From: ADVANCED INHALATION THERAPIES (AIT) LTD.
To: AIT THERAPEUTICS, INC.
Reel/Frame 046234/0061 →
FIRST LIEN SECURITY AGREEMENT Recorded Apr 18, 2018
From: SENSORMEDICS CORPORATION
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 045968/0865 →
SECOND LIEN SECURITY AGREEMENT Recorded Apr 18, 2018
From: SENSORMEDICS CORPORATION
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 045782/0851 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 4, 2017
From: PULMONOX TECHNOLOGIES CORPORATION
To: ADVANCED INHALATION THERAPIES (AIT) LTD.
Reel/Frame 043779/0488 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 15, 2008
From: MILLER, CHRISTOPHER C.
To: PULMONOX TECHNOLOGIES CORPORATION
Reel/Frame 020538/0986 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 15, 2008
From: STENZLER, ALEX
To: SENSORMEDICS CORPORATION
Reel/Frame 020538/0106 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 11, 2006
From: MILLER, CHRISTOPHER C.
To: PULMONOX TECHNOLOGIES CORPORATION
Reel/Frame 017749/0959 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 11, 2006
From: STENZLER, ALEX
To: SENSORMEDICS CORPORATION
Reel/Frame 017749/0964 →
SECURITY INTEREST Recorded Apr 7, 2006
From: THERANOX, INC.
To: VIASYS HOLDINGS INC.
Reel/Frame 017435/0358 →